Effects of a standard hyperbaric oxygen treatment protocol on pulmonary function

E. Thorsen, L. Aanderud, T.B. Aasen


ABSTRACT: The prescription of hyperbaric oxygen (HBO) therapy for disorders not related to diving is increasing. Pulmonary oxygen toxicity is well known, but the effect of the cumulative oxygen exposure corresponding to a standard HBO treatment protocol has not been quantified before.

Twenty patients (10 male) had 21 HBO treatments at a partial pressure of oxygen of 240 kPa for 90 min daily. None had any previous lung disease and all had normal chest radiography and lung function at the start of the study. Dynamic lung volumes, forced expiratory flows and the transfer factor of the lung for carbon monoxide (Tl,CO) were measured before the HBO treatment, on days 7, 14 and 21 during treatment and then 3–4 weeks after treatment.

A reduction in small airways conductance is consistent with other studies where total oxygen exposures have been below the limit causing toxic pulmonary effects traditionally measured as a reduction in vital capacity. This effect is not considered to be of any clinical significance for patients treated with hyperbaric oxygen unless repeated treatment series are to be given.

Recompression and hyperbaric oxygen (HBO) are used in the treatment for diving-related diseases such as decompression sickness and arterial gas embolism. For a long time HBO has also been shown to be effective in carbon monoxide poisoning and anaerobic infections. More recently, HBO has been shown to have supplementary effects in the treatment of other disorders characterized by local ischaemia. An increase in local oxygen supply due to an increased gradient for diffusion is achieved by increasing the partial pressure of oxygen (P02) in inspired gas. This results in local stimulation of fibroblast proliferation and collagen synthesis, angiogenesis and enhanced granulocyte function and peroxidase activity in ischaemic tissue. In this way, HBO treatment is an effective adjunct in the treatment of osteoradionecrosis, chronic osteomyelitis, diabetic leg ulcers and radiation-induced proctitis and cystitis. On an experimental basis, HBO treatment is currently evaluated as a supplement in the treatment of several other disorders. Indications for HBO treatment have been worked out by the Undersea and Hyperbaric Society [1], differentiating between indications where HBO has been shown to have a definite effect based on controlled clinical studies and indications where HBO still has to be considered experimental. In this setting, HBO treatment is usually given for 90 min daily at a P02 of 200–280 kPa for 20–30 days.

Toxic pulmonary effects of exposure to hyperoxia are well known. There is a dose-dependent reduction in vital capacity with continuous exposure to a P02 >50 kPa, as characterized by CLARK and LAMBERTSEN [2]. It has also been shown that this effect is attenuated by intermittent exposure up to the same cumulative dose of oxygen [3] and tolerance to the oxidative stress develops. HBO treatment protocols and diving procedures are based on these dose–response relationships and practical experience. Serious pulmonary oxygen toxicity has not been reported with this form of HBO treatment. However, systematic studies to quantify the effect on pulmonary function of commonly used HBO treatment protocols are lacking.

Methods

Patients

Twenty consecutive patients (10 male) undergoing treatment for ischaemic leg or foot ulcers, chronic osteomyelitis, delayed healing of fractures with pseudarthrosis or pelvic radionecrosis were included in the study. Patients with lung disease, former irradiation of the head, neck or thorax as part of the treatment for the primary disease, current smokers and patients with radiologically abnormal
Hyperbaric oxygen treatment

HBO treatment was given daily in the morning on 21 consecutive days. The patients were compressed in a hyperbaric chamber to a pressure of 240 kPa within 10–15 min. They were then given oxygen by an oronasal mask at a pressure of 240 kPa in three cycles of 30 min, interrupted by breathing air at a pressure of 240 kPa for two periods of 5 min in-between. Thereafter, they were decompressed by breathing air at a total pressure of 240 kPa for two periods breathing treatment for 21 days. Three cycles of oxygen of 30 min at an oxygen tension (PO2) of 240 kPa are given, interrupted by two periods breathing air at a total pressure of 240 kPa (PO2 = 50 kPa).

Results

All patients, except for one previous smoker whose TL,CO was 58% of predicted, had lung function within the normal predicted range at the start of the study (table 1). Four patients (one male) reported slight nonproductive coughing during the last week of treatment, which subsided during the follow-up period.

There were no significant changes in FVC, FEF25% or PEF (table 2). There were significant reductions in FEV1 (p<0.01), FEF25–75%, (p<0.01), FEF50% and FEF75% (p< 0.01) at the end of the HBO treatment period. The mean reduction in FEV1 was 4.4±1.7% and in FEF25–75% 10.3±6.1%. The gradual fall in these parameters during the treatment period had stopped at the follow-up examination, but thereafter. Measurements of lung function included forced expiratory lung volumes, forced expiratory flows and the transfer factor of the lung for carbon monoxide (TL,CO). The measurements were made on a Morgan Benchmark lung function testing apparatus (PK Morgan, Kent, UK). All measurements were taken by the same technician at the same time of the day.

The forced vital capacity (FVC), forced expiratory volume in one second (FEV1) and peak expiratory flow rate (PEF) were taken as the highest readings obtained from at least three satisfactory forced expiratory manoeuvres. Mean forced mid-expiratory flow rate (FEF25–75%) and forced expiratory flow rates at 25, 50 and 75% of FVC expired (FEF25%, FEF50% and FEF75%) were taken as the best values from flow–volume loops not differing by >5% from the highest FVC. TL,CO was measured by the single breath-holding technique. Effective alveolar volume (VA) was measured simultaneously by helium dilution and the transfer coefficient for carbon monoxide (Kco) was calculated as TL,CO/VA. An earlobe or fingertip blood sample was analysed for haemoglobin concentration on a Hemoglobin Photometer (Mecatronic AB, Helsingborg, Sweden) just before the lung function measurements. A correction in TL,CO to a haemoglobin concentration of 146 g·L−1 (TL,CO,corr) was made [4]. The better of the two measurements of TL,CO was used in the analysis.

Measurements of lung function were made according to the standardized procedures of the European Respiratory Society (ERS) [5, 6]. Volume calibration of the spirometer and temperature, pressure, saturated (BTPS) condition. At the start of HBO treatment, the patients’ baseline lung function was compared with the reference values of the ERS for FVC, FEV1 and TL,CO [5, 6].

Statistics

Changes in the lung function variables were calculated as the percentage difference from the first measurement before HBO treatment on each follow-up examination. Differences from this baseline were tested using a paired t-test with the Bonferroni method of adjusting the level of significance. A p-value <0.01 was considered to be significant. Separate analyses in males and females were performed. Any relationship between changes in the lung function variables and age or baseline lung function was tested with simple correlation analysis. All results are given as mean±SD.

Results

All patients, except for one previous smoker whose TL,CO was 58% of predicted, had lung function within the normal predicted range at the start of the study (table 1). Four patients (one male) reported slight nonproductive coughing during the last week of treatment, which subsided during the follow-up period.

There were no significant changes in FVC, FEF25% or PEF (table 2). There were significant reductions in FEV1 (p<0.01), FEF25–75%, (p<0.01), FEF50% and FEF75% (p< 0.01) at the end of the HBO treatment period. The mean reduction in FEV1 was 4.4±1.7% and in FEF25–75% 10.3±6.1%. The gradual fall in these parameters during the treatment period had stopped at the follow-up examination, but

---

**Table 1.** Subject characteristics and pulmonary function before hyperbaric oxygen treatment

<table>
<thead>
<tr>
<th></th>
<th>Males</th>
<th>Females</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age yrs</td>
<td>54±18</td>
<td>46±12</td>
</tr>
<tr>
<td>Height cm</td>
<td>181±8</td>
<td>162±6</td>
</tr>
<tr>
<td>Body mass kg</td>
<td>79±13</td>
<td>58±8</td>
</tr>
<tr>
<td>FVC L</td>
<td>4.9±0.82</td>
<td>3.67±0.47</td>
</tr>
<tr>
<td>% pred</td>
<td>103±57</td>
<td>109±10</td>
</tr>
<tr>
<td>FEV1 L</td>
<td>3.71±0.65</td>
<td>2.93±0.61</td>
</tr>
<tr>
<td>% pred</td>
<td>99±7</td>
<td>104±9</td>
</tr>
<tr>
<td>TL,CO mmol·min⁻¹·kPa⁻¹</td>
<td>9.72±1.19</td>
<td>7.55±2.32</td>
</tr>
<tr>
<td>% pred</td>
<td>97±7</td>
<td>95±17</td>
</tr>
</tbody>
</table>

FVC: forced vital capacity; % pred: percentage of predicted value; FEV1: forced expiratory volume in one second; TL,CO: transfer factor of the lung for carbon monoxide.

Findings in the lung parenchyma were excluded. Four had stopped smoking >1 yr before the study, six had stopped smoking in the last year before the study and 10 were never-smokers. Their age, height, body mass and pulmonary function at the start of the study are given in table 1.

---

**Fig. 1.** Daily oxygen exposure of patients having hyperbaric oxygen treatment for 21 days. Three cycles of oxygen of 30 min at an oxygen tension (PO2) of 240 kPa are given, interrupted by two periods breathing air at a total pressure of 240 kPa (PO2 = 50 kPa).
had not returned to pretreatment values. FEV1 and FEF25–75%, were still significantly reduced by 3.5±3.2% (p<0.01) and 10.7±8.4% (p<0.001), respectively. The box plots in figure 2 show the median and range of changes in FEV1 and TL,CO. The outliers at different times follow-up are represented by different subjects. Their exclusion from the analysis did not alter the statistical significance of the changes.

There was a significant reduction in TL,CO on day 21 of treatment only and TL,CO was completely normalized 1 month later. After correction for changes in haemoglobin concentration, the change in TL,CO was not significant.

There were no changes in VA and, thus, the changes in KCO showed the same pattern as the changes in TL,CO.

There was no significant difference between males and females for any changes in the lung function variables. The relative changes in the lung function variables did not correlate with their baseline value or with age.

**Discussion**

Recent studies have shown that reductions in small airways conductance and TL,CO may precede changes in vital capacity with continuous oxygen exposure [7, 8] and that the exposure to hyperoxia contributes to the long-term effects of diving on the lung [9]. In this study with intermittent exposure to hyperoxia, which is substantially different from the continuous low-dose exposure during a saturation dive, the same pattern of changes in pulmonary function took place without any changes in vital capacity.

The changes were small, but cannot readily be attributed to differences in the technique of performing a forced expiratory manoeuvre between examinations. With greater effort at the start of the manoeuvre, FEV1 and forced expiratory flows at 25, 50 and 75% of FVC expired; PEF: peak expiratory flow; TL,CO: transfer factor of the lung for carbon monoxide; TL,CO,corr: correction in TL,CO to a haemoglobin concentration of 146 g·L⁻¹; VA: alveolar volume. **: p<0.01; ***: p<0.001.

### Table 2. Changes in lung function during hyperbaric oxygen (HBO) treatment and at 4 weeks' follow-up in 10 male and 10 female patients

<table>
<thead>
<tr>
<th>Before HBO</th>
<th>% change after 7 days' treatment</th>
<th>% change after 14 days' HBO treatment</th>
<th>% change after 21 days' HBO treatment</th>
<th>% change 4 weeks after end of HBO treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>FVC L</td>
<td>4.32±0.92</td>
<td>-1.5±2.4</td>
<td>-1.0±1.5</td>
<td>-0.7±1.6</td>
</tr>
<tr>
<td>FEV1 L</td>
<td>3.32±0.74</td>
<td>-2.0±2.4</td>
<td>-3.2±1.9</td>
<td>-4.2±1.7**</td>
</tr>
<tr>
<td>FEP25–75% L·s⁻¹</td>
<td>3.08±1.28</td>
<td>-3.9±7.5</td>
<td>-8.6±5.2**</td>
<td>-10.3±6.7***</td>
</tr>
<tr>
<td>FEP25% L·s⁻¹</td>
<td>7.79±2.12</td>
<td>-1.1±7.1</td>
<td>-4.5±8.2</td>
<td>-3.2±6.7</td>
</tr>
<tr>
<td>FEP50% L·s⁻¹</td>
<td>4.55±1.71</td>
<td>-3.0±8.4</td>
<td>-8.6±7.3**</td>
<td>-8.8±9.0**</td>
</tr>
<tr>
<td>FEP75% L·s⁻¹</td>
<td>1.47±0.89</td>
<td>-5.7±11.4</td>
<td>-12.6±6.5***</td>
<td>-11.3±10.0**</td>
</tr>
<tr>
<td>PEF L·s⁻¹</td>
<td>8.55±1.96</td>
<td>-0.9±6.4</td>
<td>-0.5±7.7</td>
<td>-1.9±6.4</td>
</tr>
<tr>
<td>TL,CO mmol·min⁻¹·kPa⁻¹</td>
<td>8.64±1.99</td>
<td>-0.1±3.8</td>
<td>-2.2±4.1</td>
<td>-4.4±5.4**</td>
</tr>
<tr>
<td>TL,CO,corr mmol·min⁻¹·kPa⁻¹</td>
<td>8.46±2.18</td>
<td>0.3±5.2</td>
<td>-0.8±5.7</td>
<td>-3.4±7.0</td>
</tr>
<tr>
<td>VA L</td>
<td>5.70±1.29</td>
<td>1.2±1.6</td>
<td>1.2±1.5</td>
<td>1.5±1.6</td>
</tr>
</tbody>
</table>

The mean difference ±SD from the baseline before HBO treatment is given for each variable. FVC: forced vital capacity; FEV1: forced expiratory volume in one second; FEP25–75%: mean forced mid-expiratory flow rate; FEP25%, FEP50%, FEP75%: forced expiratory flows at 25, 50 and 75% of FVC expired; PEF: peak expiratory flow; TL,CO: transfer factor of the lung for carbon monoxide; TL,CO,corr: correction in TL,CO to a haemoglobin concentration of 146 g·L⁻¹; VA: alveolar volume. **: p<0.01; ***: p<0.001.
tests strictly according to the procedures of the ERS on the same instrument with the same trained technician, measurement error will be reduced to a minimum.

Pulmonary oxygen toxicity is well characterized with respect to changes in vital capacity in response to continuous exposures to partial pressures of oxygen >50 kPa [2]. The concept of units pulmonary toxic dose (UPTD) as introduced by Clark and Lambertsen [2], is widely used for calculating acceptable oxygen exposure under different conditions such as in diving procedures and treatment tables for diving-related disease. Less is known about changes in other lung function variables, in particular in response to exposure to low levels of hyperoxia. In a study with continuous exposure to a PO2 of 40–50 kPa for 28 days, as in a deep saturation dive, where no changes in vital capacity were expected or found, there was a decrease in the forced expiratory flow rates at low lung volumes and in TL, CO. The reduction in the flow rates was linear, as judged from the daily measurements during the exposure [8], and persisted up to 3 yrs after the exposure [9]. There was also a reduction in TL, CO of 10% after correction for changes in haemoglobin concentration which was normalized 1 month after the exposure. In another study, in which no changes in vital capacity were predicted or found, with continuous exposure to a PO2 of 300 kPa for 3.5 h [7], there were significant reductions in FEV1, and FEF25–75% of 5.9 and 11.8%, respectively, and a significant increase in phase III of the single-breath nitrogen washout test (δ-N2). A reduction in small airways conductance may thus take place before changes in vital capacity are seen, and this study supports these findings.

Exposure to hyperoxia reduces the stimulus for haemoglobin and red blood cell production and, after saturation dives, a reduction in haemoglobin concentration of 5–8% is usually seen [8, 12]. The reduction in TL, CO in this study could apparently be explained by the reduction in haemoglobin concentration. This could, however, be a statistical coincidence since the variance in TL, CO corr is larger than in TL, CO because of the additional variance caused by measurement error of haemoglobin concentration. The changes in TL, CO are small however and, as in saturation dives, normalized 1 month after the exposure.

Oxygen toxicity is attenuated when the exposure is intermittent, implying that a cumulative dose, which would have resulted in a reduction in vital capacity if given continuously, can be given intermittently without resulting in changes in vital capacity. This development of tolerance to hyperoxia has also been demonstrated in survival studies of animals exposed to hyperoxia [13] and in cell cultures where there is a stimulation to increased synthesis of antioxidant enzymes [14]. These enzymes are essential in the detoxification of oxygen radicals With the HBO treatment protocols in common use, the daily exposure is equivalent to 275 UPTD, which is not expected or found, there was a decrease in forced expiratory flow rates at low lung volumes and in TL, CO. The reduction in TLC, CO normalized 1 month after the exposure. In a study with continuous exposure to a PO2 of 40–50 kPa for 4 weeks. As for changes in vital capacity with oxygen exposure, the dose–response relationships may be exponential and not linear and there are still too few studies to attempt to model the effect on other lung function variables in healthy subjects. The susceptibility to oxidative stress and induction of defence mechanisms may be very different in healthy subjects than in patients who have this treatment for some underlying disease, which already may stress defence mechanisms.

In conclusion, the reduction in pulmonary function after three weeks of hyperbaric oxygen treatment is not considered to be of any clinical significance unless repeated treatment series are considered or pulmonary function is reduced before treatment. If so, the risk of pulmonary barotrauma has to be considered as a contra-indication for hyperbaric oxygen treatment in addition to the risk of a further reduction in lung function.

References